ClinConnect ClinConnect Logo
Search / Trial NCT06996561

Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphine in Postoperative Pain Management

Launched by DR. ASMA ABDUS SALAM · May 21, 2025

Trial Information

Current as of July 24, 2025

Not yet recruiting

Keywords

Genetic Variation, Nalbuphine, Opioids, Polymorphism

ClinConnect Summary

This clinical trial is investigating how genetic differences among patients might affect the effectiveness of a pain medication called Nalbuphine after surgery. The researchers want to understand if certain genes can predict how well Nalbuphine works for managing pain following various types of abdominal surgeries, such as gallbladder removal, hernia repair, and hysterectomy. The goal is to learn more about pain management in order to improve patient care and help address issues related to opioid use.

To participate in the study, you need to be an adult between 18 and 70 years old who is scheduled for a surgery lasting 2 to 4 hours. You will first provide a small blood sample before your surgery, and then receive Nalbuphine as part of your anesthesia. After surgery, another blood sample will be taken, and your pain levels and any side effects will be monitored for 24 hours. It's important to know that this study is not recruiting participants yet, and some individuals, like those with certain medical conditions or taking specific medications, may not be eligible to join.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. All adult men or women
  • 2. Age 18 to 70 years
  • 3. ASA criteria 1,2 and 3
  • 4. Abdomino-pelvic surgeries (open hernia repair, appendicectomy, open cholecystectomy, laparotomy, hysterectomy, cystectomy) lasting 2-4 hours
  • Exclusion Criteria:
  • 1. Surgical procedure duration lasting more than 4 hours
  • 2. Patients taking anti fungal fluconazole, anticoagulant (Warfarin or Clopidogrel) SNRI (Amitryptalline), Rifampicin or Buprenorphine,
  • 3. History of hypersensitivity or allergy to opioids,
  • 4. Pregnant or breastfeeding mothers,
  • 5. History of narcotic dependency, addiction, and withdrawal
  • 6. Patients experiencing any adverse side effects or complications during surgical procedure requiring intensive care admission
  • 7. Refusing to participate in the study
  • 8. Surgical procedures utilizing other modes of intraoperative analgesia e.g epidural analgesia or nerve blocks

About Dr. Asma Abdus Salam

Dr. Asma Abdus Salam is a dedicated clinical trial sponsor renowned for her commitment to advancing medical research and improving patient outcomes. With a robust background in clinical pharmacology and extensive experience in managing complex trials, she leads initiatives that prioritize safety, efficacy, and ethical standards. Dr. Abdus Salam collaborates with multidisciplinary teams to design and implement innovative study protocols, ensuring compliance with regulatory guidelines while fostering an environment of scientific integrity. Her passion for translating research findings into tangible healthcare solutions positions her as a respected leader in the clinical trial landscape.

Locations

Karachi, Sindh, Pakistan

Patients applied

0 patients applied

Trial Officials

Talat Mirza, FCPS PhD

Study Director

Ziauddin University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported